Research programme: HIV fusion inhibitors - Immunomedics/Karolinska Institute

Drug Profile

Research programme: HIV fusion inhibitors - Immunomedics/Karolinska Institute

Alternative Names: cP4/D10-(T20)4; h734-(T20)4; hLL2-(T20)4; IgG-(T20)4

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Immunomedics; Karolinska Institute
  • Class Immunoconjugates; Monoclonal antibodies; Peptides
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-1-infections in Sweden (SC, Injection)
  • 23 Jul 2012 Pharmacodynamics data from a preclinical trial in HIV-1 infections released by Karolinska Institute and Immunomedics
  • 01 Jul 2012 Preclinical development for HIV-1 infections in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top